Overview
Medhavi Gupta is an Oncologist and a Hematologist in South Weymouth, Massachusetts. Dr. Gupta is rated as an Experienced provider by MediFind in the treatment of HER-2 Positive Breast Cancer. Her top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Paget Disease of the Breast, and Neuroendocrine Tumor.
Her clinical research consists of co-authoring 16 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE SNP
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- EPO
- POS
- HMO
- INDEMNITY
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- MANAGED MEDICAID PLAN
- MEDICARE ASSISTANCE PROGRAM
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- HMO
- EPO
- HMO
- POS
- PPO
- MEDICARE DISCOUNT CARD
- MEDICARE PDP
- OTHER MEDICARE
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
101 Columbian St, South Weymouth, MA 02190
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Dana-Farber Cancer Institute, Breast Oncology Program
Dr. Tolaney is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School. She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer. She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy.She is a member of the National Cancer Institute Breast Cancer Steering Committee and is Vice Chair for Late-Stage Development in Breast Cancer in the Alliance for Clinical Trials in Oncology. Her research has been funded by the Breast Cancer Research Foundation and Susan G. Komen. She currently chairs multiple phase 3 trials in breast cancer and serves on several steering committees for practice-changing trials. Her work has been published in journals such as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, and others. She received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital. Dr. Tolaney is rated as an Elite provider by MediFind in the treatment of HER-2 Positive Breast Cancer. Her top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, and Inflammatory Breast Cancer.
Brigham And Women's Hospital, Division Of Breast Surgery
Dr. Waks received her undergraduate degree from Princeton University in 2006 and her MD degree from Harvard Medical School in 2011. She completed residency training in internal medicine at Brigham and Women's Hospital, where she subsequently served an additional year as a Chief Resident in Internal Medicine. She completed fellowship training in medical oncology at Dana-Farber/Partners CancerCare, then joined the staff of the Breast Oncology Center at Dana-Farber Cancer Institute. Dr. Waks is rated as a Distinguished provider by MediFind in the treatment of HER-2 Positive Breast Cancer. Her top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Angiosarcoma.
Beth Israel Deaconess Medical Center - Hematology/Oncology
Nadine Tung is an Internal Medicine specialist and an Oncologist in Boston, Massachusetts. Dr. Tung is rated as an Elite provider by MediFind in the treatment of HER-2 Positive Breast Cancer. Her top areas of expertise are Breast Cancer, Ovarian Cancer, HER-2 Positive Breast Cancer, Salpingo-Oophorectomy, and Hormone Replacement Therapy (HRT).
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Breast CancerDr. Gupta isExperienced. Learn about Breast Cancer.
- Colorectal CancerDr. Gupta isExperienced. Learn about Colorectal Cancer.
- HER-2 Positive Breast CancerDr. Gupta isExperienced. Learn about HER-2 Positive Breast Cancer.
- Neuroendocrine TumorDr. Gupta isExperienced. Learn about Neuroendocrine Tumor.
- Paget Disease of the BreastDr. Gupta isExperienced. Learn about Paget Disease of the Breast.
- Pancreatic CancerDr. Gupta isExperienced. Learn about Pancreatic Cancer.